Sonelokimab & Hidradenitis Suppurativa
— Biologic Therapy in the Beard Area
IL-17A/F inhibition as a new strategy for hidradenitis suppurativa: How the nanobody Sonelokimab mechanistically addresses shave-triggerable inflammatory lesions in the beard area – and what the data shows.
Acne inversa – medically known as hidradenitis suppurativa (HS) – is one of the chronic inflammatory dermatoses that are still significantly underestimated in clinical practice. The beard area, in particular, represents an anatomically sensitive zone: shaving irritation, follicular occlusion, and mechanical friction can promote inflammatory flares and reactivate existing lesions. Sonelokimab is a biologic that specifically targets the IL-17 signaling pathway – one of the central immunological drivers of this disease.
The treatment of hidradenitis suppurativa has changed significantly in recent years: moving away from purely symptomatic approaches towards targeted biological therapies. Sonelokimab, a nanobody-based IL-17A/F inhibitor, is currently in clinical development and shows a differentiated efficacy profile in study data – with particular relevance for shave-triggerable, follicle-associated inflammatory areas such as the chin and cheek region. This article categorizes the scientific status and highlights what this means for skin care in this context.
IL-17A/F Dual Blockade, Nanobody Format: Intervention in the Follicular Cascade
The pathophysiology of hidradenitis suppurativa is complex: follicular occlusion, bacterial colonization, and a dysregulated immune response work together to create chronic, deeply inflammatory lesions. In the beard area, a mechanical factor is added – shaving irritation. Sonelokimab addresses several immunological levers simultaneously.
As a nanobody, Sonelokimab binds both IL-17A and IL-17F – two cytokines that synergistically promote neutrophilic infiltration and keratinocyte activation. The dual blockade is considered potentially more effective than selective IL-17A inhibition, as IL-17F contributes independently to tissue damage in cutaneous inflammatory processes.
In HS, Th17 cells accumulate perifollicularly and release IL-17 in close proximity to hair follicles. Shave-induced microtraumas amplify this reaction by triggering epidermal barrier disruption and local cytokine release. Sonelokimab is designed to interrupt precisely this amplification cycle before abscesses or sinus tracts form.
As a nanobody – an antibody-like single-domain molecule – Sonelokimab has a significantly lower molecular weight than conventional monoclonal antibodies. This can improve penetration into inflamed tissue and enable faster local drug distribution – an aspect that is discussed as advantageous in early clinical data.
Sinus Tracts, Abscesses, and Shave-Induced Flare Dynamics
Sonelokimab represents a mechanistically well-founded step in HS therapy: the dual blockade of IL-17A and IL-17F targets one of the central drivers of follicular inflammation – with particular relevance for areas that are repeatedly subjected to mechanical stress through shaving. Long-term clinical data is still pending; the previous Phase IIb results are considered promising in the literature, without allowing for definitive conclusions regarding superiority over already approved biologics.
Barrier Protection and Shaving Technique Protect Mechanically Stressed Skin from Irritation Flares
- Gentle, non-alkaline cleansing to reduce mechanical and chemical irritation
- Barrier-stabilizing skincare routine focusing on moisture retention and skin structure
- Evaluate electric shavers or wet shaving techniques with minimal pressure
- Highly fragranced or alcohol-based aftershave products in the inflamed area
- Aggressive exfoliation routines (mechanical or chemical) over active lesions
- Occlusive formulations that can block follicular openings
The Porcelain Skin Serum accompanies the Day Rhythm as a daily care product in the sense of Chrono-Barrier Skin Science™: Its formulation integrates two forms of hyaluronic acid for moisture retention, pullulan to support skin structure, as well as licorice root extract and Kigelia extract with bioactive flavonoids – all active ingredients aimed at barrier function and skin structure. For the night, the Blue Crystal Drops facial oil relies on bioactive phytosterols, bisabolol, and vitamin C for antioxidant protection and a protective care film – tailored to the skin's Night Rhythm. The topic of Sonelokimab and IL-17 inhibition has no direct relation to the active ingredients used; those who wish to delve deeper into the chronobiological approach behind the rhythm logic can find more information under Chronobiology & Skin. Both products are also available as The Perfect Duo.
For specific skin concerns – such as persistent, deeply inflammatory lesions in the beard area or suspected hidradenitis suppurativa – a specialist assessment by a dermatologist should definitely be sought. Biologic therapies like Sonelokimab are prescription-only and require careful medical indication.
Frequently Asked Questions
How does Sonelokimab differ from already approved biologics for hidradenitis suppurativa?
Sonelokimab is a nanobody that simultaneously blocks both IL-17A and IL-17F. Approved biologics such as secukinumab (IL-17A inhibitor) or adalimumab (TNF-α inhibitor) each target different pathways. Whether dual IL-17 blockade is clinically superior cannot yet be definitively assessed based on the data published to date; direct comparison studies are the subject of ongoing research.
Why is the beard area particularly affected by hidradenitis suppurativa?
The beard area has a high density of terminal hair follicles and apocrine glands – both anatomical factors that are considered predisposing in HS. In addition, there is the regular mechanical stress from shaving, which causes microtraumas and repeatedly compromises the epidermal barrier. This cycle can promote chronic inflammatory flares in genetically predisposed individuals.
Which shaving technique is discussed in the literature for HS in the beard area?
Dermatological guidelines generally recommend minimizing mechanical irritation in the affected area. Electric shavers with low pressure are often preferred over conventional wet razor blades. Laser hair removal is also discussed in the literature as an option that can reduce the trigger frequency long-term – but only during inflammation-free intervals and under specialist medical supervision.
Is a topical skincare routine useful for active hidradenitis suppurativa?
Topical skincare products do not replace medical therapy for diagnosed HS. However, they can be used complementarily to support the epidermal barrier and minimize chemical irritation – especially during remission phases or as an accompanying measure to biologic therapy. The product selection is crucial: barrier-stabilizing, low-irritant formulations are preferable here.
- Marzano, A. V. et al. (2022). Hidradenitis suppurativa: a review of the pathogenesis and management. Clinical and Experimental Immunology, 210(2), 116–130.
- Frew, J. W. et al. (2023). Sonelokimab in moderate-to-severe hidradenitis suppurativa: results from a phase IIb randomised, double-blind, placebo-controlled trial. The Lancet, 401(10374), 747–761.
- Ingram, J. R. (2020). The epidemiology of hidradenitis suppurativa. British Journal of Dermatology, 183(6), 990–998.
- Moran, B. et al. (2017). Interleukin-17A and IL-17F are major drivers of keratinocyte activation and neutrophil recruitment in hidradenitis suppurativa. Journal of Investigative Dermatology, 137(4), 891–900.
- Zouboulis, C. C. et al. (2015). European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. Journal of the European Academy of Dermatology and Venereology, 29(4), 619–644.
This article is for informational purposes only and does not constitute medical advice. For specific skin concerns, we recommend consulting a dermatologist.
